Filing Details

Accession Number:
0001219036-21-000024
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-25 20:32:59
Reporting Period:
2021-08-23
Accepted Time:
2021-08-25 20:32:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
899923 Myriad Genetics Inc MYGN In Vitro & In Vivo Diagnostic Substances (2835) 870494517
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1219036 S Jerry Lanchbury 320 Wakara Way
Salt Lake City UT 84108
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-23 10,000 $27.07 242,550 No 4 M Direct
Common Stock Disposition 2021-08-23 10,000 $35.57 232,550 No 4 S Direct
Common Stock Acquisiton 2021-08-23 40,000 $27.07 272,550 No 4 M Direct
Common Stock Disposition 2021-08-23 40,000 $35.07 232,550 No 4 S Direct
Common Stock Acquisiton 2021-08-24 30,000 $27.07 262,550 No 4 M Direct
Common Stock Disposition 2021-08-24 30,000 $35.57 232,550 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2021-08-23 10,000 $0.00 10,000 $27.07
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2021-08-23 40,000 $0.00 40,000 $27.07
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2021-08-24 30,000 $0.00 30,000 $27.07
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
70,000 2022-09-12 No 4 M Direct
30,000 2022-09-12 No 4 M Direct
0 2022-09-12 No 4 M Direct
Footnotes
  1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. The shares subject to this option are fully vested and exercisable.